Use of Aza-Phenylalanine Compounds For Treating Cardiac Arrhythmia
OwnerManica Cerne, Uros Urleb +3inventors
InventorsManica Cerne, Uros Urleb, Metka V. Budihna, Gorazd Drevensek, Luka Peternel
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of certain aza-phenylalanine compounds of formula (I) wherein R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, Y denotes sulfonyl or carbonyl and R2 and R4 independently represent various organic residues, in the treatment or prevention of cardiac arrhythmia and/or in treatment or prevention of diseases in association with ischemic heart conditions.
Claims13
1-10. (canceled)
A method of treating or preventing cardiac arrhythmias in a subject, wherein an effective amount of a compound of formula
- or a pharmaceutically acceptable salt or a solvate thereof is administered to the subject, whereby in formula I R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, R2 denotes a group of formula
- wherein R5 denotes hydrogen, alkyl or aryl,
- R6 and R7 each independently denote hydrogen, alkyl or —COOR11,
- R8 and R9 each independently denote alkyl or cycloalkyl,
- R10 denotes hydrogen, alkoxycarbonyl or alkylsulfonyl, and
- R11 denotes hydrogen or alkyl,
- Y denotes carbonyl or sulfonyl
- R4 denotes alkyl, alkoxy or a group of formula
- wherein R12 denotes alkyl, R14 denotes alkyl or halogen, n represents an integer number from 0 to 3, and Q forms together with the phenyl ring to which it is attached a 5- to 7-membered alicyclic ring having at one position a nitrogen atom substituted by R13, wherein R13 denotes hydrogen, alkyl or acyl.
A pharmaceutical composition for use in the treatment or prevention of cardiac arrhythmia comprising a compound of formula I
- or a pharmaceutically acceptable salt or a solvate thereof, whereby in formula I R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, R2 denotes a group of formula
- wherein R5 denotes hydrogen, alkyl or aryl,
- R6 and R7 each independently denote hydrogen, alkyl or —COOR11,
- R8 and R9 each independently denote alkyl or cycloalkyl,
- R10 denotes hydrogen, alkoxycarbonyl or alkylsulfonyl, and
- R11 denotes hydrogen or alkyl,
- Y denotes carbonyl or sulfonyl
- R4 denotes alkyl, alkoxy or a group of formula
- wherein R12 denotes alkyl, R14 denotes alkyl or halogen, n represents an integer number from 0 to 3, and Q forms together with the phenyl ring to which it is attached a 5- to 7-membered alicyclic ring having at one position a nitrogen atom substituted by R13, wherein R13 denotes hydrogen, alkyl or acyl and one or more pharmaceutically acceptable auxiliaries.
A pharmaceutical composition for use in the simultaneous treatment or prevention of cardiac arrhythmia and thrombosis comprising a compound of formula I:
- or a pharmaceutically acceptable salt or a solvate thereof, whereby in formula I R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or N-alkoxyamidino, R2 denotes a group of formula
- wherein R5 denotes hydrogen, alkyl or aryl,
- R6 and R7 each independently denote hydrogen, alkyl or —COOR11,
- R8 and R9 each independently denote alkyl or cycloalkyl,
- R10 denotes hydrogen, alkoxycarbonyl or alkylsulfonyl, and
- R11 denotes hydrogen or alkyl,
- Y denotes carbonyl or sulfonyl
- R4 denotes alkyl, alkoxy or a group of formula
- wherein R12 denotes alkyl, R14 denotes alkyl or halogen, n represents an integer number from 0 to 3, and Q forms together with the phenyl ring to which it is attached a 5- to 7-membered alicyclic ring having at one position a nitrogen atom substituted by R13, wherein R13 denotes hydrogen, alkyl or acyl and one or more pharmaceutically acceptable auxiliaries.
Dependencies are inferred from the claim text.